Publications

Detailed Information

Radiosurgical Treatment of Vestibular Schwannomas in Patients with Neurofibromatosis Type 2

DC Field Value Language
dc.contributor.authorPhi, Ji Hoon-
dc.contributor.authorKim, Dong Gyu-
dc.contributor.authorChung, Hyun-Tai-
dc.contributor.authorLee, Joongyub-
dc.contributor.authorJung, Hee-Won-
dc.contributor.authorPaek, Sun Ha-
dc.date.accessioned2012-06-08T07:33:25Z-
dc.date.available2012-06-08T07:33:25Z-
dc.date.issued2009-01-15-
dc.identifier.citationCANCER; Vol.115 2; 390-398ko_KR
dc.identifier.issn0008-543X-
dc.identifier.urihttps://hdl.handle.net/10371/76920-
dc.description.abstractBACKGROUND: The radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2 (NF2) is controversial. The authors investigated the radiologically proven tumor control rate after gamma knife radiosurgery. The factors that affect tumor control and serviceable hearing preservation were analyzed. METHODS: Thirty-six lesions in 30 patients were included. The median lengths of the clinical and radiologic follow-ups were 48.5 months and 36.5 months, respectively. The median tumor volume was 3.2 cm(3). The mean marginal dose was 12.1 grays (Gy) (range, 8-14 Gy) at an isodose line of 50%+/- 0.6%. The Kaplan-Meier method and Cox proportional hazards model were used for the statistical analyses. RESULTS: The actuarial tumor control rate was 81%, 74%, and 66%, respectively, in the first, second, and fifth years. Five tumors required a salvage surgery because of tumor control failure. A low marginal dose and a young age at radiosurgery were associated with poor tumor control. Of the 16 tumors with which ipsilateral hearing was 4 serviceable, the actuarial serviceable hearing preservation rates were 50%, 45%, and 33%, respectively, in the first, second, and fifth years. Better ipsilateral hearing (Gardner-Robertson grade 1, compared with grade 2) at the time of radiosurgery was associated with significantly greater serviceable hearing preservation. CONCLUSIONS: Gamma knife radiosurgery for vestibular schwannomas in NF2 patients provided 5-year tumor A control in approximately two-thirds of patients and preserved serviceable hearing in approximately one-third. The rates of other cranial nerve deficits were low, and no secondary malignancy was observed. Radiosurgery should be included in treatment options for NF2 patients. Cancer 2009;115:390-8. (C) 2009 American Cancer Society.ko_KR
dc.language.isoenko_KR
dc.publisherJOHN WILEY & SONS INCko_KR
dc.subjectvestibular schwannomako_KR
dc.subjecthearing preservationko_KR
dc.subjectneurofibromatosis type 2ko_KR
dc.subjectgamma knife radiosurgeryko_KR
dc.titleRadiosurgical Treatment of Vestibular Schwannomas in Patients with Neurofibromatosis Type 2ko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor피지훈-
dc.contributor.AlternativeAuthor김동규-
dc.contributor.AlternativeAuthor정현태-
dc.contributor.AlternativeAuthor이중엽-
dc.contributor.AlternativeAuthor백선하-
dc.contributor.AlternativeAuthor정희원-
dc.identifier.doi10.1002/cncr.24036-
dc.citation.journaltitleCANCER-
dc.description.citedreferenceThomas C, 2007, J NEUROSURG, V107, P917, DOI 10.3171/JNS-07/11/0917-
dc.description.citedreferencePhi JH, 2007, J NEUROSURG, V107, P727, DOI 10.3171/JNS-07/10/0727-
dc.description.citedreferenceMassager N, 2007, J NEUROSURG, V107, P733, DOI 10.3171/JNS-07/10/0733-
dc.description.citedreferenceChopra R, 2007, INT J RADIAT ONCOL, V68, P845, DOI 10.1016/j.ijrobp.2007.01.001-
dc.description.citedreferenceRowe J, 2007, NEUROSURGERY, V60, P860, DOI 10.1227/01.NEU.0000255426.08926.95-
dc.description.citedreferenceFerner RE, 2007, LANCET NEUROL, V6, P340-
dc.description.citedreferenceMathieu D, 2007, NEUROSURGERY, V60, P460, DOI 10.1227/01.NEU.0000255340.26027.53-
dc.description.citedreferencePollock BE, 2006, NEUROSURGERY, V59, P77, DOI 10.1227/01.NEU.0000219217.14930.14-
dc.description.citedreferenceEvans DGR, 2006, J MED GENET, V43, P289, DOI 10.1136/jmg.2005.036319-
dc.description.citedreferencePollock BE, 2006, NEUROSURGERY, V58, P241, DOI 10.1227/01.NEU.0000194833.66593.8B-
dc.description.citedreferenceDOHERTY JK, 2006, CURR OPIN OTOLARYNGO, V14, P305-
dc.description.citedreferenceCombs SE, 2005, INT J RADIAT ONCOL, V63, P75, DOI 10.1016/j.ijrobp.2005.01.055-
dc.description.citedreferencePaek SH, 2005, CANCER, V104, P580, DOI 10.1002/cncr.21190-
dc.description.citedreferenceBaser ME, 2005, J MED GENET, V42, P540, DOI 10.1136/jmg.2004.029504-
dc.description.citedreferenceChan AW, 2005, NEUROSURGERY, V57, P60, DOI 10.1227/01.NEU.0000163091.12239.BB-
dc.description.citedreferenceEvans DGR, 2005, BRIT J NEUROSURG, V19, P5, DOI 10.1080/02688690500081206-
dc.description.citedreferenceChung HT, 2004, INT J RADIAT ONCOL, V59, P1116, DOI 10.1016/j.ijrobp.2003.12.032-
dc.description.citedreferenceMasuda A, 2004, OTOL NEUROTOL, V25, P150-
dc.description.citedreferenceXiao GH, 2003, GENE CHROMOSOME CANC, V38, P389, DOI 10.1002/gcc.10282-
dc.description.citedreferenceRowe JG, 2003, J NEUROL NEUROSUR PS, V74, P1288-
dc.description.citedreferenceBaser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/01.wco.0000053583.70044.ab-
dc.description.citedreferenceMoffat DA, 2003, EUR ARCH OTO-RHINO-L, V260, P12, DOI 10.1007/s00405-002-0503-9-
dc.description.citedreferenceRegis J, 2002, J NEUROSURG, V97, P1091-
dc.description.citedreferenceBari ME, 2002, BRIT J NEUROSURG, V16, P284, DOI 10.1080/02688690220148888-
dc.description.citedreferenceBrackmann DE, 2001, NEUROSURGERY, V49, P274-
dc.description.citedreferenceAndrews DW, 2001, INT J RADIAT ONCOL, V50, P1265-
dc.description.citedreferenceYu CP, 2000, J NEUROSURG, V93, P82-
dc.description.citedreferenceFuss M, 2000, INT J RADIAT ONCOL, V48, P1381-
dc.description.citedreferenceMassick DD, 2000, LARYNGOSCOPE, V110, P1843-
dc.description.citedreferenceThomsen J, 2000, AM J OTOL, V21, P364-
dc.description.citedreferenceKida Y, 2000, SURG NEUROL, V53, P383-
dc.description.citedreferenceSubach BR, 1999, J NEUROSURG, V90, P815-
dc.description.citedreferenceKondziolka D, 1998, NEW ENGL J MED, V339, P1426-
dc.description.citedreferenceEvans DGR, 1998, J MED GENET, V35, P450-
dc.description.citedreferenceSamii M, 1997, NEUROSURGERY, V40, P696-
dc.description.citedreferenceTROFATTER JA, 1993, CELL, V72, P791-
dc.description.citedreferenceBALDWIN D, 1991, J NEUROSURG, V74, P910-
dc.description.citedreferenceGARDNER G, 1988, ANN OTO RHINOL LARYN, V97, P55-
dc.description.tc13-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share